Enterococcus

IFF Celebrates Achievements of Leading Scientists Across Multiple Fields

Retrieved on: 
Tuesday, October 24, 2023
Knowledge, Science, Gene editing, National Inventors Hall of Fame, Escherichia coli, NYSE, Health, Food, Biotechnology, CRISPR, TM, Invention, Salmonella, Livestock, Research, Creativity, Clostridium perfringens, All rights reserved, SM, Enterococcus, Bacteria, University of California, San Diego, University, Île-de-France Clusters, NIHF, Infection, Pharmaceutical industry, Danisco, Ghent University

NEW YORK, Oct. 24, 2023 /PRNewswire/ -- IFF (NYSE: IFF)—an industry leader in food, beverage, health, biosciences and scent—this week will celebrate groundbreaking achievements in science excellence. Dr. Filip Van Immerseel and Dr. Jack A. Gilbert will receive the IFF Science and Microbiome Science Awards, for their research advancements in the fields of animal nutrition & health and microbiome.[1] Additionally, IFF scientist Dr. Philippe Horvath is being inducted into the National Inventors Hall of Fame® (NIHF) on Oct. 26 for his seminal research on CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) that helped revolutionize the gene editing field.

Key Points: 
  • "At IFF, we believe honoring scientific excellence from our scientists and academics is a great tribute to our heritage of innovation," said Dr. Casper Vroemen, executive vice president, chief R&D and sustainability officer, IFF.
  • "On behalf of the IFF scientific community, I'm proud to celebrate three renowned scientists who are pushing the limits of science to create a better world."
  • IFF Science Award: Filip Van Immerseel of Ghent University, Belgium, was selected for his groundbreaking work in animal nutrition & health.
  • IFF, the IFF Logo, and all trademarks and service marks denoted with TM, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted.

Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023

Retrieved on: 
Tuesday, October 17, 2023
Efficacy, Staphylococcus, Methicillin-resistant Staphylococcus aureus, Ambrose, Abstract, Treatment, Clinical, Circulatory system, MRSA, Biomedical Advanced Research and Development Authority, BARDA, Enterococcus faecalis, Infection, ASPR, MSSA, IDSA, Isolates, Laboratory, Liolios Xirolivaditis, Staphylococcus aureus, PK/PD models, SAB, ABSSSI, CABP, Bronchopneumonia, Administration for Strategic Preparedness and Response, Streptococcus pneumoniae, Prescription Drug User Fee Act, Duke University School of Medicine, Infectious Diseases Society of America, Randomness, Development, Administration, Safety, Patient, PDUFA, HHS, Pharmaceutical industry, Vaccine, Ceftobiprole, Litherland, Enterococcus, Allschwil, Streptococcus, Bloodstream infections

Dr. Marc Engelhardt, Chief Medical Officer of Basilea, stated: “The data presented at IDWeek provide further evidence for the potent antimicrobial activity of ceftobiprole against MRSA and other clinically relevant pathogens.

Key Points: 
  • Dr. Marc Engelhardt, Chief Medical Officer of Basilea, stated: “The data presented at IDWeek provide further evidence for the potent antimicrobial activity of ceftobiprole against MRSA and other clinically relevant pathogens.
  • It also provides results of pharmacokinetic-pharmacodynamic modeling supporting the dosing regimens to treat severe bacterial infections from the successful clinical phase 3 studies.
  • Abstract #1946 – In Vitro Activity of Ceftobiprole against Staphylococcus aureus Bacteremia Isolates from the United States (2018–2020) – L. Duncan, M. Castanheira, J. I.
  • Smart, M. E. Jones, P. G. Ambrose, K. Litherland
    Abstract #2561 – Population Pharmacokinetic Analyses for Ceftobiprole Using Data from Phase 1 and 3 Studies – A. P. Cammarata, K. Litherland, M. C. Safir, S. M. Bhavnani, M. Saulay, J. I.

Study Published in Science Translational Medicine Shows Exbaq’s Experimental Vaccine Protects Against Many of the Most Dangerous Antibiotic Resistant Superbugs Causing Hospital Acquired Infections

Retrieved on: 
Thursday, October 5, 2023
Patent, Partnership, Klebsiella pneumoniae, Infection, Methicillin-resistant Staphylococcus aureus, Homeland, Homeland security, Innovation, Acinetobacter baumannii, IND, Fungus, National Institute of Allergy and Infectious Diseases, Fungal infection, Hulk, Laboratory, Pseudomonas aeruginosa, Patient, FDA, Mucormycosis, R01, Macrophage, Escherichia coli, Immune system, USC, Bangladesh Technical Education Board, Vancomycin-resistant Enterococcus, ESBL, Korea Disease Control and Prevention Agency, Blood, Enterococcus, Translational medicine, Denise Spellberg, NIH, Vaccine, Pharmaceutical industry, Klebsiella, Science

Multiple studies in different laboratories have confirmed the vaccine protected against serious infections within 24 hours and lasts for up to 28 days.

Key Points: 
  • Multiple studies in different laboratories have confirmed the vaccine protected against serious infections within 24 hours and lasts for up to 28 days.
  • Early data suggest that a second dose may extend the window to prevent infection.
  • The study was published in Science and Translational Medicine.
  • These infections are often caused by highly antibiotic-resistant superbugs, many of which are targeted by this new ExBaq vaccine.

Recce Pharmaceuticals Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Retrieved on: 
Friday, August 4, 2023
Patent, Intellectual property, Inhalation, Australian patent law, Pathogenic bacteria, Conditioned place preference, Cytomegalovirus, HIV, EBV, SARS-CoV-2, Streptococcus pyogenes, Coronavirus, COVID-19, Recce, Gonorrhea, Skin, ASX, FSE, Burn, Staphylococcus, Shingles, Escherichia coli, Severe acute respiratory syndrome outbreak, Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae, Simplex, PCT, Viral disease, Urinary tract infection, Pseudomonas aeruginosa, Administration, Neisseria meningitidis, Biology, Ross River virus, Viral, Infection, Bacteria, Family, Virus, HCMV, Disease, RCE, Pharmaceutical industry, Vaccine, Proteus, Serratia, Enterococcus

SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We are thrilled to receive this new family of intellectual property, granted by the Australian Patent Office, with further market monopolies reinforcing opportunities among a significant range of bacterial and viral pathogens,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Viral infections may be caused by a range of viruses, such as coated viruses (e.g., lipid-coated viruses), including herpes, human immunodeficiency virus (HIV), cytomegalovirus, and influenza.
  • Other examples include Influenza A, Ross River virus, and coronavirus, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

The dirty truth about your phone – and why you need to stop scrolling in the bathroom

Retrieved on: 
Monday, April 24, 2023
Infection, Human, Norovirus, Rotavirus, Urinary tract infection, Citrobacter, COVID-19, Escherichia coli, Diphtheria, Centers for Disease Control and Prevention, COVID, Staphylococcus, Hygiene, Gardening, Somatosensory system, School, Cooking, Streptococcus, Risk, Time, Tuberculosis, Sanitation, Water, Stockholm Environment Institute US Center, Federal Communications Commission, Klebsiella, Bacteria, System, Research, Virus, Meningitis, Skin, Consumer electronics, Mobile phone, Vaccine, Proteus, Micrococcus, Enterococcus, Actinomycetota, Pseudomonas

The microbial infection risk of your phone is much less appreciated – but it’s very real.

Key Points: 
  • The microbial infection risk of your phone is much less appreciated – but it’s very real.
  • All of which can transfer microbes onto your phone along with food deposits for those microbes to eat.
  • But given how disgusting and germ-infested phones can be, maybe it’s time to think more about mobile phone hygiene.

Germs, bacteria, viruses

    • Hands pick up bacteria and viruses all the time and are recognised as a route for acquiring infection.
    • A number of studies conducted on the microbiological colonisation of mobile phones show that they can be contaminated with many different kinds of potentially pathogenic bacteria.
    • Phones contain plastic which can harbour and transmit viruses some of which (the common cold virus) can live on hard plastic surfaces for up to a week.
    • Other viruses such as COVID-19, rotavirus (a highly infectious stomach bug that typically affects babies and young children), influenza and norovirus – which can cause serious respiratory and gut infections – can persist in an infectable form for several days.

Clean your phone

    • Do not spray sanitisers directly onto the phone and keep liquids away from connection points or other phone openings.
    • When not at home, keep your phone in your pocket, or bag and use a disposable paper list of to-do items, rather than constantly consulting your phone.
    • Touch your phone with clean hands – washed with soap and water or disinfected with alcohol-based hand sanitiser.
    • You might also want to occasionally sanitise your phone charger when you are cleaning your phone.

Recce Pharmaceuticals to be Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Retrieved on: 
Tuesday, April 11, 2023
Patent, Inhalation, Australian patent law, Veterans' Preference Act of 1944, Cytomegalovirus, HIV, EBV, SARS-CoV-2, Streptococcus pyogenes, Recce, Gonorrhea, Skin, ASX, FSE, Burn, Staphylococcus, Shingles, Escherichia coli, Severe acute respiratory syndrome outbreak, Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae, Simplex, Varicella zoster virus, PCT, Viral disease, Urinary tract infection, Pseudomonas aeruginosa, Administration, Neisseria meningitidis, Patient, Biology, Ross River virus, Viral, Infection, Bacteria, Virus, HCMV, Disease, RCE, Pharmaceutical industry, Vaccine, Proteus, Serratia, Enterococcus

SYDNEY, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We would like to thank the Australian Patent Office for this notification of intent, which further validates the potential of our new class of anti-infectives to help patients with a broad range of bacterial and viral infections,” said James Graham, Chief Executive Officer of Recce Pharmaceutical.
  • Viral infections that may be caused by a range of viruses, such as coated viruses (e.g., lipid-coated viruses), include herpes, human immunodeficiency virus (HIV), cytomegalovirus, and influenza.
  • Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome.

CHOP-led Study Shows that Antibiotic-Resistant Microbes in the Gut Make C. difficile More Infectious

Retrieved on: 
Wednesday, November 16, 2022
Health, Doctor of Philosophy, University of Minnesota Medical School, Philadelphia, Hospital, Clostridioides difficile infection, RNA, IBD, Infection, VRE, Prussia, University of Virginia, Environment, Collection, Metabolomics, Clostridioides difficile (bacteria), University, Vancomycin-resistant Enterococcus, Vanderbilt University School of Medicine, Assistant, Ornithine, Pathology, Research, Association, Organic acid, Patient, Nutrient, Inflammatory bowel disease, University of Florida, University of Pittsburgh, Children's Hospital of Philadelphia, DOI, Medical laboratory, Virulence, Arginine, Gastrointestinal tract, CHOP, Public health, Dietary supplement, Pharmaceutical industry, Nature, Child, Enterococcus

PHILADELPHIA, Nov. 16, 2022 /PRNewswire/ -- Clostridioides difficile, often referred to as C. difficile or C. diff, is a bacterium that causes severe intestinal illness and, as its name suggests, can be difficult to study and treat. Approximately 1 in 6 patients infected with C. difficile will be reinfected within two months. Yet scientists have not figured out why C. difficile infection is more difficult to treat in some patients versus others. The human gut is filled with trillions of microbes, and these microbes influence the virulence of various pathogens, but until now, scientists had little understanding of how C. difficile cooperates with the rich collection of microorganisms in the gastrointestinal tract.

Key Points: 
  • Yet scientists have not figured out why C. difficile infection is more difficult to treat in some patients versus others.
  • Prior studies have shown that adults infected with C. difficile also have high levels of Enterococcus in their gut and that vancomycin-resistant Enterococcus (VRE) frequently co-infects patients with C. difficile.
  • They also observed a positive correlation between C. difficile burdens and ornithine, supporting a key role for this amino acid in C. difficile infection.
  • difficile."

UMF Corporation Calls for Nominations for 14th Annual National Hygiene Specialist® Excellence Award

Retrieved on: 
Thursday, November 10, 2022
Hospital, Methicillin-resistant Staphylococcus aureus, EVS, Research, Disinfectant, Risk, Health, Education, VRE, Death, Multimedia, CDC, Staphylococcus, View, Virus, Paola Lattus, Science, Patient, Bacteria, UMF, Vancomycin-resistant Enterococcus, Infection, Enterococcus, Clostridioides difficile (bacteria), MRSA, COVID-19, Pharmaceutical industry, Medicine

NORTHBROOK, Ill., Nov. 10, 2022 /PRNewswire/ -- UMF Corporation is pleased to announce that nominations are open for the 14th annual National Hygiene Specialist® Excellence Award, which acknowledges the environmental services (EVS) workers who play essential roles in reducing preventable healthcare associated infections (pHAIs). pHAIs are among the leading causes of death in the United States. Infecting 1 in 25 hospitalized patients annually, pHAIs put patients at risk, significantly increase the number of hospital days required, and add to healthcare costs. EVS staff are crucial when it comes to controlling pHAIs, which include superbugs such as Methicillin-resistant Staphylococcus aureus (MRSA), Clostridioides difficile (C. diff), Vancomycin-resistant Enterococcus (VRE), and COVID-19. Nominations are open through Dec. 31, 2022.

Key Points: 
  • NORTHBROOK, Ill., Nov. 10, 2022 /PRNewswire/ -- UMF Corporation is pleased to announce that nominationsare open for the 14th annual National Hygiene Specialist Excellence Award , which acknowledges the environmental services (EVS) workers who play essential roles in reducing preventable healthcare associated infections (pHAIs).
  • "In the United States, infections acquired in healthcare facilities kill more than 75,000 people every year," said UMF CEO George Clarke.
  • While we established our National Hygiene Specialist Excellence Award more than a decade ago, it has never been more important to acknowledge and celebrate these workers who serve as a first line of defense in preventing the spread of pHAIs."
  • The National Hygiene Specialist Excellence Award is an opportunity to recognize their critical contributions.

Acurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022 Conference Call and Provide Business Update

Retrieved on: 
Tuesday, November 1, 2022
Security (finance), Marketing, MRSA, Clostridioides, DNA, Infection, IIIC, Clostridioides difficile (bacteria), Securities and Exchange Commission (Philippines), Annual report, Methicillin-resistant Staphylococcus aureus, Gram, VRE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Gram-positive bacteria, CDI, Maintenance, GAIN, Private Securities Litigation Reform Act, Company, Clostridioides difficile infection, FDA, Enterococcus, Patient, Food, Fast Track, QIDP, CDC, Act, Firmicutes, GPSS, DRSP, Pharmaceutical industry, Actinobacteria

It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.

Key Points: 
  • It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.
  • The Company successfully completed Phase 1 and Phase 2a clinical trials of ibezapolstat.
  • The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI.
  • Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.

Peptilogics to Present Data at IDWeek 2022 on PLG0206, an Engineered Antimicrobial Peptide Targeting Bacteria Causing Periprosthetic Joint Infection

Retrieved on: 
Thursday, October 20, 2022
Biotechnology, Pharmaceutical, Surgery, General Health, Health, Medical Devices, Infectious Diseases, Clinical Trials, LinkedIn, United States Department of Health and Human Services, MIC, MRSA, Cystic Fibrosis Foundation, Biomedical Advanced Research and Development Authority, Founders Fund, Development, Klebsiella, Gram-negative bacteria, Debridement, Human services, Infection, QIDP, Cons, MSSA, Patient, Escherichia coli, Hospital, Research, Twitter, Staphylococcus aureus, Mortality, Inflammation, Enterobacter cloacae, Artificial intelligence, Technology, Solution, Staphylococcus, TKA, Cystic fibrosis, Administration, Department, Gram-positive bacteria, Klebsiella pneumoniae, Drug of last resort, Enterococcus, Enterobacter, Bacteria, MDR, Fast Track, Gram, S. aureus, Surgeon, Cancer, Algorithm, Pharmaceutical industry, Vaccine, Wellcome

Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, is presenting two posters featuring preclinical data from its antimicrobial peptide, PLG0206, at IDWeek 2022 .

Key Points: 
  • Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, is presenting two posters featuring preclinical data from its antimicrobial peptide, PLG0206, at IDWeek 2022 .
  • The studies demonstrate the potent activity of PLG0206 against bacteria that cause periprosthetic joint infections (PJI), including multidrug resistant (MDR) bacteria.
  • PJI is the most common complication of joint replacement surgery and is a life-changing event for patients.
  • MDR related infections pose a significant concern to patients as well as society in both the short- and long-term.